22.418 articles found

Changes in cerebral glucose metabolism in patients with Parkinson disease with dementia after cholinesterase inhibitor therapy.

Lee PH, Yong SW, An YS.

J Nucl Med · 2008-11-07

DOI: 10.2967/jnumed.108.054668PMID: 18997034

Both pre- and post-lesion experiential therapy is beneficial in 6-hydroxydopamine dopamine-depleted female rats.

Jadavji NM, Metz GA.

Neuroscience · 2008-11-07

DOI: 10.1016/j.neuroscience.2008.10.054PMID: 19032978

The appropriateness of routine medication treatment for schizophrenia.

Young AS, Niv N, Cohen AN, Kessler C, McNagny K.

Schizophr Bull · 2008-11-07

DOI: 10.1093/schbul/sbn138PMID: 18997159

COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE

SNOW ALAN D, NGUYEN BETH P, CASTILLO GERARDO M, SANDERS VIRGINIA J, LAKE THOMAS P, LARSEN LESLEY, WEAVERS REX T, LORIMER STEPHEN D, LARSEN DAVID S, COFFEN DAVID L, COFFEN CHRLOTTE.

· 2008-11-04

4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES

JANKOWSKI ORION D, WESSON KIERON E, MOLLARD PAUL, SHRADER WILLIAM D.

· 2008-11-04

4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES

JANKOWSKI ORION D, WESSON KIERON E, MOLLARD PAUL, SHRADER WILLIAM D.

· 2008-11-04

Treadmill training for the treatment of gait disturbances in people with Parkinson's disease: a mini-review.

Herman T, Giladi N, Hausdorff JM.

J Neural Transm (Vienna) · 2008-11-04

DOI: 10.1007/s00702-008-0139-zPMID: 18982238

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.

Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, Sussman NM, Istradefylline 6002-US-013 Study Group.

Mov Disord · 2008-11-01

DOI: 10.1002/mds.22095PMID: 18831530

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.

Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, Rascol O.

Mov Disord · 2008-11-01

DOI: 10.1002/mds.22218PMID: 18932271

Orally disintegrating selegiline for the treatment of Parkinson's disease.

Löhle M, Storch A.

Expert Opin Pharmacother · 2008-11-01

DOI: 10.1517/14656566.9.16.2881PMID: 18937619

Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches.

Paul S.

Bioessays · 2008-11-01

DOI: 10.1002/bies.20852PMID: 18937370

The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.

Elmer LW, Bertoni JM.

Expert Opin Pharmacother · 2008-11-01

DOI: 10.1517/14656566.9.16.2759PMID: 18937611